Latham & Watkins represented TA Associates, a leading global private equity firm, in its investment in Diatech Pharmacogenetics, a leader in pharmacogenetics and cancer precision medicine diagnostics.

Upon completion of the transaction, TA Associates will start a strategic collaboration with Diatech’s management and founders, that will retain a majority interest in the company.

Latham & Watkins advised TA Associates on corporate matters with a team led by partners Stefano Sciolla and Giorgia Lugli, with Federica Ventura and Nicholas Luraghi. Partner Cesare Milani and Edoardo Cassinelli advised on the regulatory aspects of the deal.